Evidence map›Paper›PMID 31638194›Full record

SynthesisInternational journal of oncology2019

Assessment of biochemical recurrence of prostate cancer (Review).

Xiaozeng Lin, Anil Kapoor, Yan Gu, Mathilda Jing Chow, Hui Xu, Pierre Major, Damu Tang

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaozeng LinDepartment of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Anil KapoorThe Research Institute of St. Joe's Hamilton, St. Joseph's Hospital, Hamilton, ON L8N 4A6, Canada.
Yan GuDepartment of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Mathilda Jing ChowDepartment of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.
Hui XuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Pierre MajorDivision of Medical Oncology, Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Damu TangDepartment of Medicine, McMaster University, Hamilton, ON L8S 4K1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The assessment of the risk of biochemical recurrence (BCR) is critical in the management of males with prostate cancer (PC). Over the past decades, a comprehensive effort has been focusing on improving risk stratification; a variety of models have been constructed using PC‑associated pathological features and molecular alterations occurring at the genome, protein and RNA level. Alterations in RNA expression (lncRNA, miRNA and mRNA) constitute the largest proportion of the biomarkers of BCR. In this article, we systemically review RNA‑based BCR biomarkers reported in PubMed according to the PRISMA guidelines. Individual miRNAs, mRNAs, lncRNAs and multigene panels, including the commercially available signatures, Oncotype DX and Prolaris, will be discussed; details related to cohort size, hazard ratio and 95% confidence intervals will be provided. Mechanistically, these individual biomarkers affect multiple pathways critical to tumorigenesis and progression, including epithelial‑mesenchymal transition (EMT), phosphatase and tensin homolog (PTEN), Wnt, growth factor receptor, cell proliferation, immune checkpoints and others. This variety in the mechanisms involved not only validates their associations with BCR, but also highlights the need for the coverage of multiple pathways in order to effectively stratify the risk of BCR. Updates of novel biomarkers and their mechanistic insights are considered, which suggests new avenues to pursue in the prediction of BCR. Additionally, the management of patients with BCR and the potential utility of the stratification of the risk of BCR in salvage treatment decision making for these patients are briefly covered. Limitations will also be discussed.

Indexed as

CarcinogenesisClinical Decision-MakingDisease-Free SurvivalDisease ProgressionFeasibility StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKallikreinsMaleNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapyRisk AssessmentKallikreinsKLK3 protein, humanProstate-Specific AntigenRNA

Identifiers

PMID31638194
PMCPMC6831208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.